Imiquimod; an international update on therapeutic uses in dermatology
Imiquimod, the first member of a new class of immune response modifiers, is approved for the treatment of external genital and perianal warts. The clinical effect of imiquimod stems from cytokine‐induced activation of the immune system. Topical application of imiquimod elevates the production of cyt...
Gespeichert in:
| Veröffentlicht in: | International journal of dermatology 2002-11, Vol.41 (11), p.810-816 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 816 |
|---|---|
| container_issue | 11 |
| container_start_page | 810 |
| container_title | International journal of dermatology |
| container_volume | 41 |
| creator | Tyring, Stephen Conant, Marcus Marini, Mario Van Der Meijden, Willem Washenik, Ken |
| description | Imiquimod, the first member of a new class of immune response modifiers, is approved for the treatment of external genital and perianal warts. The clinical effect of imiquimod stems from cytokine‐induced activation of the immune system. Topical application of imiquimod elevates the production of cytokines, including the principal cytokine for antiviral activity, interferon‐α. This is the initial event in an immunological cascade resulting in the stimulation of the innate immune response as well as the cell‐mediated pathway of acquired immunity. This immune modification mediates the indirect antiviral, antiproliferative and antitumor activity of imiquimod in vivo. These properties highlight the potential of imiquimod not only as an effective treatment for genital warts, but also as a treatment for other cutaneous viral infections and cutaneous neoplasms. |
| doi_str_mv | 10.1046/j.1365-4362.2002.01597.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_222879930</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>267247941</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4297-74bb66621e19c2139d3bea76d17f9bec0a5e36eddd56d96dbfd3882505785b7d3</originalsourceid><addsrcrecordid>eNqNkEtP3DAYRS1UBFPKX0BRpS4T_IjtWIgFonSYChVUBlhaTvwFPM1jsBN15t-TNCPYdmVbPvfq6iAUEZwQnIrTVUKY4HHKBE0oxjTBhCuZbPbQbPoQjH5CM4wJiRXm6hB9DmE1PBkl6QE6JDTlDBM6Q1eL2r32rm7tWWSayDUd-MZ0rm1MFfVrazqI2ibqXsCbNfSdK6I-QBjAyIKvTddW7fP2C9ovTRXgeHceoYcfV8vL6_jmdr64vLiJi5QqGcs0z4UQlABRBSVMWZaDkcISWaocCmw4MAHWWi6sEjYvLcsyyjGXGc-lZUfo69S79u1rD6HTq7Yf9lZBU0ozqRTDA5RNUOHbEDyUeu1dbfxWE6xHfXqlR0t61KdHffqfPr0Zoie7_j6vwX4Ed74G4NsOMKEwVelNU7jwwQ2VKpXjhvOJ--sq2P73AL34-X28Dfl4yrvQweY9b_wfLSSTXD_9muu7JZn_Jst7_cjeAL4Tmh0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>222879930</pqid></control><display><type>article</type><title>Imiquimod; an international update on therapeutic uses in dermatology</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Tyring, Stephen ; Conant, Marcus ; Marini, Mario ; Van Der Meijden, Willem ; Washenik, Ken</creator><creatorcontrib>Tyring, Stephen ; Conant, Marcus ; Marini, Mario ; Van Der Meijden, Willem ; Washenik, Ken</creatorcontrib><description>Imiquimod, the first member of a new class of immune response modifiers, is approved for the treatment of external genital and perianal warts. The clinical effect of imiquimod stems from cytokine‐induced activation of the immune system. Topical application of imiquimod elevates the production of cytokines, including the principal cytokine for antiviral activity, interferon‐α. This is the initial event in an immunological cascade resulting in the stimulation of the innate immune response as well as the cell‐mediated pathway of acquired immunity. This immune modification mediates the indirect antiviral, antiproliferative and antitumor activity of imiquimod in vivo. These properties highlight the potential of imiquimod not only as an effective treatment for genital warts, but also as a treatment for other cutaneous viral infections and cutaneous neoplasms.</description><identifier>ISSN: 0011-9059</identifier><identifier>EISSN: 1365-4632</identifier><identifier>DOI: 10.1046/j.1365-4362.2002.01597.x</identifier><identifier>PMID: 12453012</identifier><identifier>CODEN: IJDEBB</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Science Ltd</publisher><subject>Adjuvants, Immunologic - therapeutic use ; Aminoquinolines - therapeutic use ; Biological and medical sciences ; Carcinoma - drug therapy ; Condylomata Acuminata - drug therapy ; Dermatologic Agents - therapeutic use ; DNA Virus Infections - drug therapy ; Humans ; Imiquimod ; Immunocompromised Host ; Medical sciences ; Papillomaviridae ; Papillomavirus Infections - drug therapy ; Pharmacology. Drug treatments ; Skin Neoplasms - drug therapy ; Skin, nail, hair, dermoskeleton</subject><ispartof>International journal of dermatology, 2002-11, Vol.41 (11), p.810-816</ispartof><rights>2003 INIST-CNRS</rights><rights>Copyright Blackwell Scientific Publications Ltd. Nov 2002</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4297-74bb66621e19c2139d3bea76d17f9bec0a5e36eddd56d96dbfd3882505785b7d3</citedby><cites>FETCH-LOGICAL-c4297-74bb66621e19c2139d3bea76d17f9bec0a5e36eddd56d96dbfd3882505785b7d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1046%2Fj.1365-4362.2002.01597.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1046%2Fj.1365-4362.2002.01597.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14369470$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12453012$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tyring, Stephen</creatorcontrib><creatorcontrib>Conant, Marcus</creatorcontrib><creatorcontrib>Marini, Mario</creatorcontrib><creatorcontrib>Van Der Meijden, Willem</creatorcontrib><creatorcontrib>Washenik, Ken</creatorcontrib><title>Imiquimod; an international update on therapeutic uses in dermatology</title><title>International journal of dermatology</title><addtitle>Int J Dermatol</addtitle><description>Imiquimod, the first member of a new class of immune response modifiers, is approved for the treatment of external genital and perianal warts. The clinical effect of imiquimod stems from cytokine‐induced activation of the immune system. Topical application of imiquimod elevates the production of cytokines, including the principal cytokine for antiviral activity, interferon‐α. This is the initial event in an immunological cascade resulting in the stimulation of the innate immune response as well as the cell‐mediated pathway of acquired immunity. This immune modification mediates the indirect antiviral, antiproliferative and antitumor activity of imiquimod in vivo. These properties highlight the potential of imiquimod not only as an effective treatment for genital warts, but also as a treatment for other cutaneous viral infections and cutaneous neoplasms.</description><subject>Adjuvants, Immunologic - therapeutic use</subject><subject>Aminoquinolines - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Carcinoma - drug therapy</subject><subject>Condylomata Acuminata - drug therapy</subject><subject>Dermatologic Agents - therapeutic use</subject><subject>DNA Virus Infections - drug therapy</subject><subject>Humans</subject><subject>Imiquimod</subject><subject>Immunocompromised Host</subject><subject>Medical sciences</subject><subject>Papillomaviridae</subject><subject>Papillomavirus Infections - drug therapy</subject><subject>Pharmacology. Drug treatments</subject><subject>Skin Neoplasms - drug therapy</subject><subject>Skin, nail, hair, dermoskeleton</subject><issn>0011-9059</issn><issn>1365-4632</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkEtP3DAYRS1UBFPKX0BRpS4T_IjtWIgFonSYChVUBlhaTvwFPM1jsBN15t-TNCPYdmVbPvfq6iAUEZwQnIrTVUKY4HHKBE0oxjTBhCuZbPbQbPoQjH5CM4wJiRXm6hB9DmE1PBkl6QE6JDTlDBM6Q1eL2r32rm7tWWSayDUd-MZ0rm1MFfVrazqI2ibqXsCbNfSdK6I-QBjAyIKvTddW7fP2C9ovTRXgeHceoYcfV8vL6_jmdr64vLiJi5QqGcs0z4UQlABRBSVMWZaDkcISWaocCmw4MAHWWi6sEjYvLcsyyjGXGc-lZUfo69S79u1rD6HTq7Yf9lZBU0ozqRTDA5RNUOHbEDyUeu1dbfxWE6xHfXqlR0t61KdHffqfPr0Zoie7_j6vwX4Ed74G4NsOMKEwVelNU7jwwQ2VKpXjhvOJ--sq2P73AL34-X28Dfl4yrvQweY9b_wfLSSTXD_9muu7JZn_Jst7_cjeAL4Tmh0</recordid><startdate>200211</startdate><enddate>200211</enddate><creator>Tyring, Stephen</creator><creator>Conant, Marcus</creator><creator>Marini, Mario</creator><creator>Van Der Meijden, Willem</creator><creator>Washenik, Ken</creator><general>Blackwell Science Ltd</general><general>Blackwell Science</general><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7U7</scope><scope>C1K</scope><scope>H94</scope></search><sort><creationdate>200211</creationdate><title>Imiquimod; an international update on therapeutic uses in dermatology</title><author>Tyring, Stephen ; Conant, Marcus ; Marini, Mario ; Van Der Meijden, Willem ; Washenik, Ken</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4297-74bb66621e19c2139d3bea76d17f9bec0a5e36eddd56d96dbfd3882505785b7d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Adjuvants, Immunologic - therapeutic use</topic><topic>Aminoquinolines - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Carcinoma - drug therapy</topic><topic>Condylomata Acuminata - drug therapy</topic><topic>Dermatologic Agents - therapeutic use</topic><topic>DNA Virus Infections - drug therapy</topic><topic>Humans</topic><topic>Imiquimod</topic><topic>Immunocompromised Host</topic><topic>Medical sciences</topic><topic>Papillomaviridae</topic><topic>Papillomavirus Infections - drug therapy</topic><topic>Pharmacology. Drug treatments</topic><topic>Skin Neoplasms - drug therapy</topic><topic>Skin, nail, hair, dermoskeleton</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tyring, Stephen</creatorcontrib><creatorcontrib>Conant, Marcus</creatorcontrib><creatorcontrib>Marini, Mario</creatorcontrib><creatorcontrib>Van Der Meijden, Willem</creatorcontrib><creatorcontrib>Washenik, Ken</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>International journal of dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tyring, Stephen</au><au>Conant, Marcus</au><au>Marini, Mario</au><au>Van Der Meijden, Willem</au><au>Washenik, Ken</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Imiquimod; an international update on therapeutic uses in dermatology</atitle><jtitle>International journal of dermatology</jtitle><addtitle>Int J Dermatol</addtitle><date>2002-11</date><risdate>2002</risdate><volume>41</volume><issue>11</issue><spage>810</spage><epage>816</epage><pages>810-816</pages><issn>0011-9059</issn><eissn>1365-4632</eissn><coden>IJDEBB</coden><abstract>Imiquimod, the first member of a new class of immune response modifiers, is approved for the treatment of external genital and perianal warts. The clinical effect of imiquimod stems from cytokine‐induced activation of the immune system. Topical application of imiquimod elevates the production of cytokines, including the principal cytokine for antiviral activity, interferon‐α. This is the initial event in an immunological cascade resulting in the stimulation of the innate immune response as well as the cell‐mediated pathway of acquired immunity. This immune modification mediates the indirect antiviral, antiproliferative and antitumor activity of imiquimod in vivo. These properties highlight the potential of imiquimod not only as an effective treatment for genital warts, but also as a treatment for other cutaneous viral infections and cutaneous neoplasms.</abstract><cop>Oxford, UK</cop><pub>Blackwell Science Ltd</pub><pmid>12453012</pmid><doi>10.1046/j.1365-4362.2002.01597.x</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0011-9059 |
| ispartof | International journal of dermatology, 2002-11, Vol.41 (11), p.810-816 |
| issn | 0011-9059 1365-4632 |
| language | eng |
| recordid | cdi_proquest_journals_222879930 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Adjuvants, Immunologic - therapeutic use Aminoquinolines - therapeutic use Biological and medical sciences Carcinoma - drug therapy Condylomata Acuminata - drug therapy Dermatologic Agents - therapeutic use DNA Virus Infections - drug therapy Humans Imiquimod Immunocompromised Host Medical sciences Papillomaviridae Papillomavirus Infections - drug therapy Pharmacology. Drug treatments Skin Neoplasms - drug therapy Skin, nail, hair, dermoskeleton |
| title | Imiquimod; an international update on therapeutic uses in dermatology |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T02%3A26%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Imiquimod;%20an%20international%20update%20on%20therapeutic%20uses%20in%20dermatology&rft.jtitle=International%20journal%20of%20dermatology&rft.au=Tyring,%20Stephen&rft.date=2002-11&rft.volume=41&rft.issue=11&rft.spage=810&rft.epage=816&rft.pages=810-816&rft.issn=0011-9059&rft.eissn=1365-4632&rft.coden=IJDEBB&rft_id=info:doi/10.1046/j.1365-4362.2002.01597.x&rft_dat=%3Cproquest_cross%3E267247941%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=222879930&rft_id=info:pmid/12453012&rfr_iscdi=true |